DOCSLIB.ORG

Pharmacology Review Guide

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Pharmacology Review Guide 1 SAINT BARNABAS HEALTH CARE SYSTEM Preparation for Nursing Pharmacology Test PHARMACOLOGY REVIEW GUIDE In order to successfully pass the 50 item pharmacology exam, nurses must achieve an overall score of 80%. However, nurses are only allowed to get 2 calculation questions wrong from the Drug Calculation section of the exam (3 errors in calculation questions means an automatic failure and the nurse must re-take the exam). For the calculation questions on the exam, the nurse must show all work that led to arriving at the answer. Only ONE retake is permitted. Time allotted for exam: 1 1/2 hour (90 min.). I. Categories of Medications Know the actions, use, serious side effects and specific nursing measures for administration of the following frequently ordered medications or categories of medications Cardiovascular/Antiarrhythmics Hormones – levothyroxine Beta Blockers eg. metoprolol (Synthroid) (Lopressor); atenolol (Tenormin) Agents for Depression/Sedation ACE inhibitors – eg. enalapril Fluoxetine (Prozac) (Vasotec) Lorazepam (Ativan) Digoxin (Lanoxin) Nitroglycerine: transdermal Anti-infectives/Anti-fungals patch & paste Ampicillin Adrenergics – dopamine Cefazolin (Ancef/Kefzol) infusion (Intropin) Gentamicin sulfate (Garamycin) Verapamil (Veracaps SR) Vancomycin Antidiabetic Agents Anti-inflammatory Agents Insulins: Regular, & NPH Prednisone/methylprednisolone Humalog, Humulin, Lantus Dexamethasone (Decadron) Metformin (Glucophage) NSAIDS – eg.Ibuprophen, Aleve Glyburide (Diabeta) Cox-2 Inhibitors- eg Celebrex Insulin Pen use Anticoagulants/Hematologic Agents Analgesics/Narcotics Heparin sodium Hydromorphone (Dilaudid) Warfarin sodium (Coumadin) Morphine sulfate & MS Contin Enoxaparin sodium (Lovenox) Oxycodone-acetaminophen. Dalteparin sodium (Fragmin) (Percocet) Antiulcer/Antiemetics Diuretics Famotidine (Pepcid) Hydrochlorothiazide (Esidrix) Omeprazole (Prilosec) Spironolactone (Aldactone) Ondansetron (Zofran) Furosemide (Lasix ) Flumazenil (Romazicon) 7/2005 Rev. 1/2007, 1/2010, 5/2015, 11/2015 2 Antiseizure High Alert Medications: Identified by Phenytoin sodium (Dilantin) TJC (The Joint Commission) -- concentrated KCL, concentrated NaCl,, Antidotes insulin, heparin Protamine Sulfate Naloxone HCl (Narcan) Herbal Interactions: anticoagulants and Vitamin K (Aquamephyton) ginko biloba II. Important to Know: 1. Medication administration based on RN standards of practice. 2. How to administer intramuscular injections – variations by weight, size, age. 3. Nursing responsibilities for first-dose of any medication. 4. Nursing documentation for PRN medications. 5. How to draw up and administer insulin subcutaneously and how to use an insulin pen. 6. Heparin/Lovenox/Fragmin injection techniques and sites 7. Specific lab values to be monitored for patients on Lovenox/Fragmin, Heparin, Coumadin, Vancomycin 8. How to apply topical/ transdermal medication/patches 9. IV push medications 10. How to administer eye and ear drops – adults and pediatric 11. How to administer sustained release (SR, LX, LA etc.) tablets/capsules 12. Distinguish S/S of hypoglycemia & the interventions for treating it. 13. Measures for effective pain management – dosing schedule, documentation, use of appropriate pain scale eg. FLACC, BPS, CPOT, Wong-Baker, Numeric. 14. Safety measures for administration of TPN (total parenteral nutrition) 15. How to administer meds via NG tube 16. IV administration of diluted KCl only via central line or large vein 17. Monitoring for IV infiltration of vesicants (e.g. Dopamine) 18. Heparin Infusion weight-based dosages III. Conversions 1 kg = 1000 gm 1 liter = 1000 ml 1 oz = 30 ml 1 gm = 1000 mg 1 kg = 2.2 lbs 1 tbsp = 3 tsp 1 mg = 1000 mcg 1 tsp = 5 ml 1 inch = 2.54 cm 7/2005 Rev. 1/2007, 1/2010, 5/2015, 11/2015 3 IV. Policies - The following SBHCS policies apply to the administration of medication and must be followed at all times. TOPIC GOLDEN RULES ADDITIONAL INFORMATION PAIN Patients must receive adequate If the medications ordered are not pain control. controlling the patient’s pain, a new order should be obtained from the physician. Don’t let the patient suffer. Pain assessment, interventions, Documentation includes: pain and outcomes must be assessment, treatment, comfort level documented completely achieved (the pain goal for that patient), interventions when treatment is inadequate, and new outcomes from those interventions DOUBLE To identify each patient Forms of identification include the IDENTIFICA- receiving medication, the nurse patient’s ID BAND (a must!); asking TION must use 2 forms of the patient his name, the MR number, identification. date of birth, phone number, photo license, etc. TELEPHONE All telephone orders must be The order read back and verification ORDERS completely read back and includes the patient’s name, date and verified to the physician as time of the order, the name of the soon as they are recorded on med, the dose, the route, the the medical record and frequency of administration, any BEFORE they are executed. parameters or criteria for administration. VERBAL Verbal orders can only be An emergency situation is one in ORDERS accepted in an emergency which the health of the patient would situation. be compromised if there were a delay in administering the medication. For accuracy, all verbal orders The order read-back and verification must be read back and verified includes the patient’s name, date and to the Physician completely as time of the order, the name of the soon as they are written in the med, the dose, the route, the medical record. frequency of administration, any parameters or criteria for administration. ANNOTATION Correct & complete written a. Use a leading zero in front of the FOR orders are required for each decimal dose of a medication. WRITTEN medication to be administered. Correct: 0.35 mg Incorrect .35 mg ORDERS If any part of an order is b. Do Not use a ‘trailing zero’ after a missing, unclear, illegible, whole number dose of a medication 7/2005 Rev. 1/2007, 1/2010, 5/2015, 11/2015 4 includes unacceptable Correct: 4mg Incorrect: 4.0 mg abbreviations, or does not conform to the patient’s c. Never use a range of doses or condition, the nurse must times. contact the physician to correct Correct: Percocet 1 tab. po q4h the problem or clarify the order Incorrect: Percocet 1-2 tabs q 3-4 before administering the hours. medication. MISSED Whenever a medication dose When a medication dose is missed MEDICATION has been missed, the nurse eg. the patient is off the unit, the DOSES should contact the physician to nurse should not assume that the clarify what is best for the patient can wait until the next dose is patient. due. The decision about the missed dose belongs to the physician. DANGEROUS Certain previously-acceptable WRONG RIGHT ABBREVIA- abbreviations CAN NO TIONS LONGER BE USED in the U Units medical record. IU International Units ug Micrograms, mcg The TJC and hospital policy now prohibits their use. QD/OD Daily QOD Every other day If these abbreviations appear in sc or sq Subcutaneously a medication order, the order must be clarified with the QID Four times a day physician and rewritten correctly. MS/MSO4 Morphine sulfate (morphine) MgSO4 Magnesium sulfate OS/OD/OU Left/right/both eyes AS/AD/AU Left/right/both ears V. Some Helpful Hints: Exam candidates may bring one nursing drug reference book and a calculator (extra batteries recommended) to use during the exam. Example: Mosby’s Nursing Drug Reference by Linda Skidmore-Roth; Cost: approx. $38.00. No cell phones may be brought into the exam area or used during the test. VI. Sample Conversions and Calculations: The problems below represent the types of calculations that will be presented on the nursing pharmacology exam. The answers are found at the end of this review guide. 7/2005 Rev. 1/2007, 1/2010, 5/2015, 11/2015 5 Conversions: a. 2 tsp = _____ mL f. 2 oz = _____ mL b. 450 mcg = _____ mg g. 150 lbs = _____ kg c. .048 gm = _____ mg h. 65 kg = _____ lbs d. 475 mg = _____ gm i. 4.1 mg = _____ mcg e. 3 tablespoons = _____ mL j. 2.5 inches = _____ cm Calculations: 1. A child is to receive amoxicillin 50 mg po. The medication in oral suspension is labeled 125 mg per 5 ml. How many mls should the child receive? 2. The liquid medication label reads 100 mg per 2 ml. The order is for the patient to receive 200 mg of the medication. How many mls will be administered? 3. The patient is to receive digoxin 0.25 mg IV. Digoxin is in prefilled syringes of 0.5 mg per 2 mls. How many mls will be administered by syringe? 4. The physician orders dynapen 125 mg po stat. The bottle is labeled 25 mg per ml. How many mls should be given? 5. Penicillin G sodium for injection contains 250,000 units per ml. How many units are there in 3.5 mls? 6. The doctor orders 1000 ml of D5W every 6 hours. How many mls per hour should the patient receive? 7. Calculate the drip rate for an IV of D5 ½ NS to run at 20 ml per hour using a microdrip set (60 gtts per ml). 8. The patient is to receive Keflex 1 gm P.O. On hand is Keflex 250 mg per tablet. How many tablets should be administered? 9. Garamycin comes in a concentration of 80 mg per 2ml. How many mls would be needed for a dose of 40 mg? 10. The physician orders 1 liter of NS every 8 hours. How many mls per hour should the patient receive? Using macrodrip tubing (15 gtts per ml) what is the flow rate in gtts per minute? 7/2005 Rev. 1/2007, 1/2010, 5/2015, 11/2015 6 11. The patient is to receive Ancef 1 gram every 6 hours in 100 ml of normal saline to run over 30 minutes. If microdrip tubing is used (60 gtts per ml), what is the rate of flow in drops per minute? If macrodrip tubing is used (15 gtts per ml), what is the rate of flow in drops per minute? 12.
Load more

Recommended publications
  • Pharmacology
    Pharmacology New for 2020-2021 Competitor orientation deleted from ILC. Event Summary Pharmacology provides HOSA members with the opportunity to gain knowledge and skills regarding the area of healthcare concerned with uses, effects, and modes of actions of drugs. This competitive event consists of a written test with a tie-breaker essay question. This event aims to inspire members to learn about how drugs work in the body, proper administration, and adaptations for different patients and conditions. Dress Code Competitors must be in official HOSA uniform or proper business attire. Bonus points will be awarded for proper dress. General Rules 1. Competitors in this event must be active members of HOSA-Future Health Professionals, in good standing. 2. Secondary and Postsecondary/Collegiate divisions are eligible to compete in this event. 3. Competitors must be familiar with and adhere to the “General Rules and Regulations of the HOSA Competitive Events Program (GRR)." 4. All competitors shall report to the site of the event at the time designated for each round of competition. At ILC, competitor’s photo ID must be presented prior to ALL competition rounds. Official References • Fulcher, Soto and Fulcher. Pharmacology: Principles and Applications. Elsevier, Latest edition. • Ford, Susan and Sally Roach. Roach’s Introductory Clinical Pharmacology. Wolters Kluwer, Latest edition. Written Test 5. Test Instructions: The written test will consist of 100 multiple choice items in a maximum of 90 minutes. 6. Time Remaining Announcements: There will be a verbal announcement when there are 60 minutes, 30 minutes, 15 minutes, 5 minutes, and 1 minute remaining to complete the test.
    [Show full text]
  • Surfen, a Small Molecule Antagonist of Heparan Sulfate
    Surfen, a small molecule antagonist of heparan sulfate Manuela Schuksz*†, Mark M. Fuster‡, Jillian R. Brown§, Brett E. Crawford§, David P. Ditto¶, Roger Lawrence*, Charles A. Glass§, Lianchun Wang*, Yitzhak Torʈ, and Jeffrey D. Esko*,** *Department of Cellular and Molecular Medicine, Glycobiology Research and Training Center, †Biomedical Sciences Graduate Program, ‡Department of Medicine, Division of Pulmonary and Critical Care Medicine and Veteran’s Administration San Diego Medical Center, ¶Moores Cancer Center, and ʈDepartment of Chemistry and Biochemistry, University of California at San Diego, La Jolla, CA 92093; and §Zacharon Pharmaceuticals, Inc, 505 Coast Blvd, South, La Jolla, CA 92037 Communicated by Carolyn R. Bertozzi, University of California, Berkeley, CA, June 18, 2008 (received for review May 26, 2007) In a search for small molecule antagonists of heparan sulfate, Surfen (bis-2-methyl-4-amino-quinolyl-6-carbamide) was first we examined the activity of bis-2-methyl-4-amino-quinolyl-6- described in 1938 as an excipient for the production of depot carbamide, also known as surfen. Fluorescence-based titrations insulin (16). Subsequent studies have shown that surfen can indicated that surfen bound to glycosaminoglycans, and the extent block C5a receptor binding (17) and lethal factor (LF) produced of binding increased according to charge density in the order by anthrax (18). It was also reported to have modest heparin- heparin > dermatan sulfate > heparan sulfate > chondroitin neutralizing effects in an oral feeding experiments in rats (19), sulfate. All charged groups in heparin (N-sulfates, O-sulfates, and but to our knowledge, no further studies involving heparin have carboxyl groups) contributed to binding, consistent with the idea been conducted, and its effects on HS are completely unknown.
    [Show full text]
  • ADHD Parents Medication Guide Revised July 2013
    ADHD Parents Medication Guide Revised July 2013 Attention-Deficit/Hyperactivity Disorder Prepared by: American Academy of Child & Adolescent Psychiatry and American Psychiatric Association Supported by the Elaine Schlosser Lewis Fund Physician: ___________________________________________________ Address: ___________________________________________________ ___________________________________________________ ___________________________________________________ Phone: ___________________________________________________ Email: ___________________________________________________ ADHD Parents Medication Guide – July 2013 2 Introduction Attention-Deficit/Hyperactivity Disorder (ADHD) is a neurodevelopmental disorder characterized by difficulty paying attention, excessive activity, and impulsivity (acting before you think). ADHD is usually identified when children are in grade school but can be diagnosed at any time from preschool to adulthood. Recent studies indicate that almost 10 percent of children between the ages of 4 to 17 are reported by their parents as being diagnosed with ADHD. So in a classroom of 30 children, two to three children may have ADHD.1,2,3,4,5 Short attention spans and high levels of activity are a normal part of childhood. For children with ADHD, these behaviors are excessive, inappropriate for their age, and interfere with daily functioning at home, school, and with peers. Some children with ADHD only have problems with attention; other children only have issues with hyperactivity and impulsivity; most children with ADHD have problems with all three. As they grow into adolescence and young adulthood, children with ADHD may become less hyperactive yet continue to have significant problems with distraction, disorganization, and poor impulse control. ADHD can interfere with a child’s ability to perform in school, do homework, follow rules, and develop and maintain peer relationships. When children become adolescents, ADHD can increase their risk of dropping out of school or having disciplinary problems.
    [Show full text]
  • Clinical Pharmacology 1: Phase 1 Studies and Early Drug Development
    Clinical Pharmacology 1: Phase 1 Studies and Early Drug Development Gerlie Gieser, Ph.D. Office of Clinical Pharmacology, Div. IV Objectives • Outline the Phase 1 studies conducted to characterize the Clinical Pharmacology of a drug; describe important design elements of and the information gained from these studies. • List the Clinical Pharmacology characteristics of an Ideal Drug • Describe how the Clinical Pharmacology information from Phase 1 can help design Phase 2/3 trials • Discuss the timing of Clinical Pharmacology studies during drug development, and provide examples of how the information generated could impact the overall clinical development plan and product labeling. Phase 1 of Drug Development CLINICAL DEVELOPMENT RESEARCH PRE POST AND CLINICAL APPROVAL 1 DISCOVERY DEVELOPMENT 2 3 PHASE e e e s s s a a a h h h P P P Clinical Pharmacology Studies Initial IND (first in human) NDA/BLA SUBMISSION Phase 1 – studies designed mainly to investigate the safety/tolerability (if possible, identify MTD), pharmacokinetics and pharmacodynamics of an investigational drug in humans Clinical Pharmacology • Study of the Pharmacokinetics (PK) and Pharmacodynamics (PD) of the drug in humans – PK: what the body does to the drug (Absorption, Distribution, Metabolism, Excretion) – PD: what the drug does to the body • PK and PD profiles of the drug are influenced by physicochemical properties of the drug, product/formulation, administration route, patient’s intrinsic and extrinsic factors (e.g., organ dysfunction, diseases, concomitant medications,
    [Show full text]
  • I. Antihistamines Seunghoon Han* Department of Clinical Pharmacology and Therapeutics, Seoul St
    2014;22(1):13-18 TCP Translational and Clinical Pharmacology http://dx.doi.org/10.12793/tcp.2014.22.1.13 Clinical Pharmacology Review for Primary Health Care Providers: I. Antihistamines Seunghoon Han* Department of Clinical Pharmacology and Therapeutics, Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul 137-701, Korea *Correspondence: S. Han; Tel: +82-2-2258-7326, Fax: +82-2-2258-7876, E-mail: [email protected] Received 31 May 2014 Primary health care providers play a critical role in maintaining public health, and the appropri- Accepted 31 May 2014 ate use of pharmaceutical products is one of the major parts of their practice. This series of articles, pISSN: 2289-0882 entitled ‘Clinical Pharmacology Review for Primary Health Care Providers,’ is intended to help pri- mary health care providers select more appropriate prescriptions for frequently used drugs based on up-to-date information. We expect that this effort will contribute to improvements in public health and diminish unnecessary drug use. Introduction tion on the H1 receptor.[8] THERAPEU Antihistamines include some of the most frequently prescribed drugs in the primary health care environment for the symp- Generations and Classes tomatic relief of allergic diseases, the common cold, urticaria, Many primary health care providers are well-informed about T and insomnia.[1-5] The importance of antihistamines has been the different ‘generations’ of antihistamines but not about the ICS TU emphasized as the prevalence of target diseases increases.[6,7] different ‘classes’ characterized according to chemical structure. However, the appropriate use, clinical effectiveness, and target [1] This discrepancy seems reasonable because ‘inter-generation’ T populations for prescription of antihistamines are still a matter differences are more prominent than ‘inter-class’ differences.
    [Show full text]
  • Guidance for Reviewers Pharmacology/Toxicology Review Format
    Guidance for Reviewers Pharmacology/Toxicology Review Format U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Pharmacology/Toxicology May 2001 Guidance for Reviewers Pharmacology/Toxicology Review Format Additional copies are available from: Drug Information Branch (HFD-210) Center for Drug Evaluation and Research (CDER) 5600 Fishers Lane, Rockville, MD 20857, (Tel) 301-827-4570 Internet at http://www.fda.gov/der/guidance/index.htm U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Pharmacology/Toxicology May 2001 Guidance for Reviewers Table of Contents I. INTRODUCTION ....................................................................................................1 II. BACKGROUND.......................................................................................................1 III. DISCUSSION ...........................................................................................................1 A. IND REVIEW FORMAT ....................................................................................1 B. NDA REVIEW FORMAT...................................................................................1 IV. ATTACHMENTS .....................................................................................................1 A. IND REVIEW FORMAT ....................................................................................A-i B. NDA REVIEW FORMAT...................................................................................B-i
    [Show full text]
  • Department of Pharmacology (GRAD) 1
    Department of Pharmacology (GRAD) 1 faculty participate fully at all levels. The department has the highest DEPARTMENT OF level of NIH funding of all pharmacology departments and a great diversity of research areas is available to trainees. These areas PHARMACOLOGY (GRAD) include cell surface receptors, G proteins, protein kinases, and signal transduction mechanisms; neuropharmacology; nucleic acids, cancer, Contact Information and antimicrobial pharmacology; and experimental therapeutics. Cell and molecular approaches are particularly strong, but systems-level research Department of Pharmacology such as behavioral pharmacology and analysis of knock-in and knock-out Visit Program Website (http://www.med.unc.edu/pharm/) mice is also well-represented. Excellent physical facilities are available for all research areas. Henrik Dohlman, Chair Students completing the training program will have acquired basic The Department of Pharmacology offers a program of study that leads knowledge of pharmacology and related fields, in-depth knowledge in to the degree of doctor of philosophy in pharmacology. The curriculum is their dissertation research area, the ability to evaluate scientific literature, individualized in recognition of the diverse backgrounds and interests of mastery of a variety of laboratory procedures, skill in planning and students and the broad scope of the discipline of pharmacology. executing an important research project in pharmacology, and the ability The department offers a variety of research areas including to communicate results, analysis, and interpretation. These skills provide a sound basis for successful scientific careers in academia, government, 1. Receptors and signal transduction or industry. 2. Ion channels To apply to BBSP, students must use The Graduate School's online 3.
    [Show full text]
  • Beta Blocker
    Medication Information Beta Blocker Other names for this medication Acebutol Nadolol Atenolol Pindolol Bisoprolol Propanolol Carvediol Sotalol Labetalol Timolol Metoprolol There are many other names for this medication. How this medication is used This medication causes your heart to beat slower. This helps rest the heart after a heart attack. This medication helps prevent and/or reduce chest pain and irregular heart beats. It does not stop chest pain or angina after the pain has started. Bisoprolol, Carvedilol and Metoprolol can be used to prevent heart failure. They work by relaxing the blood vessels. This allows more blood to go to the heart. The more blood that goes to the heart, the more oxygen the heart gets. This helps the heart work better. Some of these medications are used to treat high blood pressure, migraine headaches and muscle tremors. Beta Blocker How to take this medication Take this medication exactly as directed by your doctor or health care provider. It must be taken regularly, even if you feel well. Do not suddenly stop taking this medication without checking with your doctor or health care provider first. Suddenly stopping this medication can cause: • chest pain • irregular heart beats • high blood pressure. When it is time to stop taking this medication your doctor or health care provider may slowly decrease the amount. If you miss a dose of this medication, take it as soon as possible. However, if it is almost time for the next dose, skip the missed dose and go back to your regular time. Do not take 2 doses at one time.
    [Show full text]
  • Pharmacology 101
    Pharmacology 101 Tyler Fischback, PharmD, BCPS, DPLA Clinical Pharmacy Manager Confluence Health Wenatchee, WA Objectives • Define Pharmacology, Pharmacokinetics and Pharmacodynamics • Understand how drug interactions work • Understand how some specific drugs behave in the body (opioids, benzodiazepines, amiodarone) • Apply pharmacology principles into practice Medication Errors and Adverse Drug Events • Error: An error of commission or omission at any step along the pathway that begins when a clinician prescribes a medication and ends when the patient actually received the medication. • ADE: Harm experienced by a patient as a result of exposure to a medication. ADE does not necessarily indicate an error or poor care. However, ~1/2 of ADEs are preventable. Anyone here ever seen a medication error or adverse drug event? Anyone here ever made a medication error? How many different prescription medications are available on the U.S. market? 1,000 So, it’s no surprise why we see so many problems………………… EXCEPT……. The real number is 10,000 Adverse Drug Events • ~1/3 of U.S. adults use 5 or more medications • Annually, ADE = 700,000 ER visits and 100,000 hospitalizations • So, is pharmacology important to your work? • Additionally, 5% of hospitalized patient experience an ADE during their stay • High risk: Anticoagulants, Opioids, Insulin, Cardiac, and Transitions of Care Adverse Drug Events, cont. • Elderly are more susceptible • Pediatrics patients more susceptible (weight-based dosing), especially liquids • Caregivers and patients admittedly
    [Show full text]
  • Physiology, Biochemistry, and Pharmacology of Transporters for Organic Cations
    International Journal of Molecular Sciences Editorial Physiology, Biochemistry, and Pharmacology of Transporters for Organic Cations Giuliano Ciarimboli Experimental Nephrology, Department of Internal Medicine D, University Hospital Münster, 48149 Münster, Germany; [email protected] This editorial summarizes the 13 scientific papers published in the Special Issue “Physiology, Biochemistry, and Pharmacology of Transporters for Organic Cations” of the International Journal of Molecular Sciences. In this Special Issue, the readers will find integrative information on transporters for organic cations. Besides reviews on physi- ology, pharmacology, and toxicology of these transporters [1–3], which offer a concise overview of the field, the readers will find original research work focusing on specific transporter aspects. Specifically, the review “Organic Cation Transporters in Human Physiology, Phar- macology, and Toxicology” by Samodelov et al. [1] summarizes well the general as- pects of physiology, pharmacology, and toxicology of transporter for organic cations. The other review “Organic Cation Transporters in the Lung—Current and Emerging (Patho)Physiological and Pharmacological Concepts” by Ali Selo et al. [2] focuses on these aspects of transporters for organic cations in the lung, an important but often ne- glected field. In the paper “Systems Biology Analysis Reveals Eight SLC22 Transporter Subgroups, Including OATs, OCTs, and OCTNs”, by performing a system biology analysis of SLC22 transporters, Engelhart et al. [4] suggest the existence of a transporter–metabolite network. They propose that, in this network, mono-, oligo-, and multi-specific SLC22 transporters Citation: Ciarimboli, G. Physiology, interact to regulate concentrations and fluxes of many metabolites and signaling molecules. Biochemistry, and Pharmacology of In particular, the organic cation transporters (OCT) subgroup seems to be associated with Transporters for Organic Cations.
    [Show full text]
  • PHARMACOLGY HOMEWORK Overdose Management Add In
    PHARMACOLGY HOMEWORK Overdose Management Add in important nursing notes for each of these medications and overdose management as well as administration route. Medication Overdose Nursing Notes (*Homework) Management (Routes) Acetaminophen Acetylcysteine Acetaminophen: (PO/PR) Route: PO, IV Max daily dose: 4000mg Acute toxicity (overdose) Monitor for S+S of hepatotoxicity (éLFTs, bilirubin, hypoglycemia, renal damage) Acetylcysteine: IV infusion: monitor for fluid overload and signs of hyponatremia such as changes in mental status Monitor for S+S of aspiration, bronchospasm, excess secretions Digitalis Digoxin Immune Fab Digoxin: (PO/IV) (Ovine, Digibind) Take apical pulse for 60sec. If < 60 BPM hold Route: IV digoxin dose and contact prescriber. Monitor serum digoxin (it has a narrow therapeutic index), potassium, magnesium, calcium. Monitor for S+S toxicity: anorexia, nausea, vomiting, diarrhea, visual disturbances, cardiac arrhythmias Digoxin Immune Fab: Skin allergy testing prior to administration for history of allergy or previous therapy of this drug Monitor cardiac status + rhythm, neurological status Toxicity reversal within an hour (adults), minutes (children) of antidote administration Monitor serum potassium, critical within first few hours; serum digoxin levels, ECG for 2-3 weeks post administration Heparin Protamine sulfate Heparin: (IV/SC) (IV) Monitor for spontaneous bleeding, thrombocytopenia Monitor aPTT levels Protamine Sulfate: Sudden drop in BP Monitor BP+ P q15-30 min Monitor aPTT Opioid Naloxone (IV-adults, Opioids:
    [Show full text]
  • Specialty Pharmacy Drug List
    Specialty Pharmacy Drug List Our Specialty Pharmacy provides patients with comprehensive support services and coordinated delivery related to high-cost oral, inhaled or injectable specialty medications, used to treat complex conditions. We are your single source for high-touch patient care management to control side effects, patient support and education to ensure compliance or continued treatment, and specialized handling and distribution of medications directly to the patient or care provider. Specialty medications may be covered under either the medical or pharmacy benefit. Please consult your insurance documentation to determine which benefit covers these medications. We offer a broad specialty medication list containing nearly 500 drugs, covering 42 therapeutic categories and specialty disease states. This list is updated with new information each quarter. Characteristics of Specialty Medications “Specialty” medications are defined as high-cost oral or injectable medications used to treat complex chronic conditions. These are highly complex medications, typically biology-based, that structurally mimic compounds found within the body. High-touch patient care management is usually required to control side effects and ensure compliance. Specialized handling and distribution are also necessary to ensure appropriate medication administration. Medications must have at least one of the following characteristics in order to be classified as a specialty medication by Magellan Rx Management. High Cost High Complexity High Touch High-cost medications
    [Show full text]